About Karius
Karius is a Healthcare company based in Redwood City (United States) founded in 2014 by Tim Blauwkamp. Developer of a non-invasive pathogen blood test for the detection of infectious diseases. Karius has raised $315 million across 5 funding rounds from investors including Tencent, Lightspeed Venture Partners and Khosla Ventures. Its chief executive, as recorded, is Alec Ford. Its website kariusdx.com draws about 11 thousand monthly visits. Karius offers products and services including Karius Spectrum. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its legal entity is KARIUS, INC. Its competitors include Inflammatix, Day Zero Diagnostics and Visby Medical; 3 of its 3 listed competitors have raised funding.
Company details
Karius was founded in 2014 and is headquartered in Redwood City, United States. The company operates in the health technology sector, focusing on diagnostics for infectious diseases. A single blood sample is analyzed through the Karius Test, which employs genomics and artificial intelligence to identify microbial pathogens. This approach supports clinicians in making informed treatment decisions quickly, without invasive procedures.
- Headquarters Redwood City, United States
- Founders Tim Blauwkamp
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website kariusdx.com
- Social LinkedIn X Facebook
- Legal Name Karius, Inc.
- Total Equity Funding$315M (USD)
in 5 rounds
- Latest Funding Round$100M (USD), Series C
May 2024
- InvestorsTencent
& 14 more
Products & Services of Karius
Karius offers a comprehensive portfolio of products and services, including Karius Spectrum.
Non-invasive blood test detecting pathogens for infectious disease diagnosis.
Apps and channels of Karius
Karius publishes 2 mobile apps with over 100 downloads.
Funding Insights of Karius
Karius has successfully raised a total of $315M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $315M
- Total Rounds 5
- Last Round Series C — $100M
- Investors Count 15
All 5 funding rounds of Karius with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $100M | Series C | – | Khosla Ventures | |
| Feb 2020 | $165M | Series B | – | SoftBank Vision Fund | |
| Nov 2018 | $25M | Debt – Conventional | – | – | |
| Aug 2017 | $50M | Series A | – | DCVC, Lightspeed Venture Partners | – |
| Sep 2016 | Seed | – | – |
15 investors in total: 15 institutional.
Investors in Karius
Karius has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Tencent, Lightspeed Venture Partners and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US | seventure.fr | Paris, France | ||
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Investment and transformation services for entrepreneurs in technology and finance sectors. | generalcatalyst.com | |||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Early-stage technology investments are targeted by this venture capital firm. | innovationendeavors.com | Palo Alto, United States | ||
Venture capital firm investing in multiple sectors | Menlo Park, United States | |||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States |
Investor details for Karius
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Karius
87 people are tracked at Karius (41 in leadership, 4 in board & advisors, 42 in team).
| Name | Role | Group |
|---|---|---|
Tim Blauwkamp | Co-Founder & Chief Scientific Officer | Leadership |
Alec Ford | CEO | Leadership |
Stacy Solorio | Chief People Officer | Leadership |
Sivan Bercovici | Chief Technology Officer & Chief Business Officer | Leadership |
Karl Hudspith | Director Of Intellectual Property | Leadership |
Sarah Park | Sr. Director, Medical Affairs | Leadership |
Bradley Perkins | Chief Medical Officer | Leadership |
Eric Kuliyev | Regional Sales Director | Leadership |
Steve Malaska | Chief Legal Officer | Leadership |
Bill Quirk | Chief Financial Officer | Leadership |
Igor D. Vilfan | Senior Director Of Research | Leadership |
Kevin Loh | Director, Marketing Ops And Sales Enablement | Leadership |
David Berman | Medical Director | Leadership |
Dr. Patricia Whaley | Director, Customer Success | Leadership |
Wendy Williams | Director Medical Science Liaison | Leadership |
Aga Zielinska | Vice President Of Program And Product | Leadership |
Kristin Jarman | Director Of Assay Development Analytics | Leadership |
Mark Rocha | Senior Director, Talent Acquisition | Leadership |
Ricardo Castillo-Galvan M.D., Mph | Medical Director, Medical Affairs | Leadership |
Michaela Kessler Pa-C | Director - Medical Science Liaison - West | Leadership |
67 more people are available in the full profile.
Complete people profiles for Karius
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Karius
3 dated milestones of Karius across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Karius is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $100.0M.
Competitors of Karius
Karius has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Day Zero Diagnostics and Visby Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. |
Detailed competitors of Karius
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Karius
The website of Karius (kariusdx.com) receives about 11K visits a month and ranks #2,447,687 among all websites worldwide, #3,344 in Biotechnology and Pharmaceuticals.
- Monthly visits11K
▲ 25.6% vs previous month
- Unique visitors3.9K
per month
- Global rank#2,447,687
among all websites
- Category rank#3,344
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.9
- Average visit1 min 14 sec
- DevicesDesktop 36% · Mobile 64%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Karius (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Karius
Complete news archive for Karius
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Karius
Karius was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Karius is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Alec Ford is the CEO of Karius, as recorded in our data.
Karius is a funded company, having raised a total of $315M across 5 funding rounds to date.
Karius was founded in 2014 and is headquartered in Redwood City, United States. The company operates in the health technology sector, focusing on diagnostics for infectious diseases. A single blood sample is analyzed through the Karius Test, which employs genomics and artificial intelligence to identify microbial pathogens. This approach supports clinicians in making informed treatment decisions quickly, without invasive procedures.
Karius's top competitors include Visby Medical, Inflammatix and Day Zero Diagnostics.
Karius offers Karius Spectrum.
Karius has 15 investors. Key investors include Tencent, Lightspeed Venture Partners, Khosla Ventures, Oxford Finance, and SoftBank Vision Fund.
Karius operates through Karius, Inc..
Yes. Karius publishes Karius Mobile Portal and 1 more app, with over 100 downloads.